Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol + fluticasone in adolescents with inadequately controlled asthma
PACTR202607586774191Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing QVM149 arm with Salmeterol + fluticasone propionate arm (2 arms). Primary endpoint: Change from baseline in trough FEV1 at Week 12. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterolfluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on PACTR202607586774191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607586774191.